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The putative thyroid-disrupting properties of bisphenol A (BPA) highlight the need for an evaluation
of fetal exposure and its consequenceon themother/newborn thyroid functions inmodels relevant to
human. The goals of this study were to characterize in sheep a relevant model for human pregnancy
and thyroid physiology, the internal exposures of the fetuses and their mothers to BPA and its main
metabolite BPA-glucuronide (Gluc), and to determine to what extent it might be associated with
thyroid disruption. Ewes were treatedwith BPA [5mg/(kg  d) sc] or vehicle from d 28 until the end of
pregnancy. Unconjugated BPA did not appear to accumulate in pregnant ewes, and its concentration
was similar in the newborns and their mothers (0.13  0.02 and 0.18  0.03 nmol/ml in cord and
maternal blood, respectively). In amniotic fluid and cord blood, BPA-Gluc concentrations were about
1300-fold higher than those of BPA. Total T4 concentrationswere decreased in BPA-treated pregnant
ewesand in the cordand the jugularbloodof their newborns (30%decrease).A similar differencewas
observed for free T4 plasma concentrations in the jugular blood of the newborns. Our results show in
a long-gestation species with a similar regulatory scheme of thyroid function as humans that BPA in
utero exposure can be associated with hypothyroidism in the newborns. If such an effect were to be
confirmedforamore relevantexposure schemetoBPA, thiswouldconstituteamajor issue forBPArisk
assessment. (Endocrinology 154: 521–528, 2013)
Bisphenol A (BPA), amajormolecule used in the plasticindustry, is now acknowledged as an endocrine dis-
ruptor that could exert deleterious effects on human
health (1, 2). Most investigations have focused on repro-
ductive functions based on the estrogen-mimetic proper-
ties of this compound. However, evidence has accumu-
lated that BPA might have negative effects on other
endocrine systems (3, 4) including thyroid function (5).
Epidemiological data obtained on a cohort of men from
infertile couples (6) and on a larger cohort of healthy
individuals (National Health and Nutrition Examina-
tion Survey cohort) (7) suggests that BPA exposure
might be associated with some degree of thyroid dis-
ruption characterized by a suggestive inverse relation-
ship between urinary BPA concentrations and total T4
concentrations.
In vivo studies inmammals looking at the effect of BPA
on thyroid function are scarce, and they have all been
performed in rodents. In one study, the physiological rise
in circulating total T4 that occurs around postnatal d 15
(PND15) was amplified in animals born to and fed by
mothers treatedwithBPA fromgestational d6 (GD6)until
weaning with an oral dose at 1 mg/(kg  d), i.e. below the
current no-observed-adverse-effect level of 5 mg/(kg  d)
(8). These changes in circulating T4 were associated with
changes in the expression of neurogranin, a thyroid-reg-
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ulated marker for neurodifferentiation, in the dentate
gyrus within the hippocampus. In another study in preg-
nant rats (9),BPAoral treatment at0.1mg/liter indrinking
water [approximately 10 g/(kg  d)] caused a transitory
decrease in the free T4 concentration in mothers in the
early postpartum period (PND0–PND7), whereas their
male offspring showed an increase in free T4 at PND7
followed by a decrease in free T4 at PND21. The signifi-
cance of these studies in terms of the risk analysis for hu-
man health is limited for two main reasons. First, the rat
is often considered controversial in terms of its relevance
to thyroid regulation in humans, in particular for devel-
opment-related issues, becauseof adifference in the timing
of the ontogenesis of thyroid function. Second, these two
studies did not provide information regarding the internal
exposure of the animals, impeding all comparisons with
known human exposure.
Evidence for the potential of BPAas a thyroid disruptor
has also arisen from results obtained with mammalian
cells and amphibian or fish models in vivo. These studies
converge to suggest that BPA can exert an antagonistic
effect on thyroid hormone (TH)-dependent mechanisms
(10–16). This effect appears to bemediated, at least in cell
models, by the increased recruitment of corepressor of the
TH nuclear receptors from the N-cor family (17, 18).
Overall, it can be considered that uncertainties remain
regarding the potential of BPA as a thyroid disruptor in vivo
in mammals. Thus, the goal of this study was to test the
hypothesis that exposure to BPA in utero can lead to thyroid
disruption in both mothers and newborns and to character-
ize at the same time the exposure of different maternal and
fetal compartments. To achieve this goal, we used the sheep
modelasananimalexhibitingsimilarpatternsof thyroidaxis
ontogenesis and regulation as humans.
Materials and Methods
Chemicals
Chemicals were purchased from Sigma-Aldrich (Saint Quen-
tin Fallavier, France) unless otherwise specified.
BPA stock solutions (500mg/ml, five different solutions used
throughout the experiment) were prepared by dissolving BPA
(99% purity) in absolute HPLC-grade ethanol. Solutions were
kept at 4 C in sealed amber glass bottles. Solutions for sc ad-
ministration (91 mg/ml) were prepared weekly by a 5.5-fold di-
lution of a stock solution in corn oil (Sigma). Solutionswere kept
at4C.Vehicle solutionswere obtainedbymixing ethanolwith
corn oil. For iv administration, the stock solution was diluted
10-fold in propanediol to obtain a 50 mg/ml solution.
Animal husbandry and treatments
The study was conducted on adult (n  15, 2–5 yr old)
Lacaune ewes in the sheep research facility of the National Vet-
erinary School of Toulouse, France. These ewes had multiple
pregnancies before being included in the experiment. Ewes were
submitted to hormonal synchronization of their estrous cycle
andwere artificially inseminatedwith fresh Lacaune ram sperm.
Then, a Blackbelly ram was introduced into the flock to mate
with the nonpregnant ewes. Finally, five vehicle- and six BPA-
treated ewes got pregnant after the artificial insemination pro-
cedure, and two others from each group got pregnant at the
following cycle (about 2 wk later) after mating the ram.
Pregnant ewes were randomly allocated to two groups: ve-
hicle orBPA treated.Groupswerebalanced forbodyweights and
fecundation modality (insemination vs. ram). Animals from the
BPA group received daily sc injections 5 mg/(kg  d) of BPA
starting at GD28 and until the end of pregnancy, whereas the
control group received an equivalent volume of vehicle. The ad-
ministered volume was regularly adjusted for the most recently
recorded body weight. The 93rd injection was performed iv to
document BPA toxico-kinetic parameters in pregnant animals.
Eweswere fedhay ad libitum andvegetable pellets. The quan-
tity of pellets was adjusted monthly to fulfill pregnancy require-
ments. The animals were kept inside under natural photoperi-
odic and temperature conditions.
Starting at GD145, lambs were delivered by cesarean section
aseptically performed under spinal anesthesia (75–125 mg lido-
caine aseptically injected in the sacrolumbar cisterna; Lurocaïne,
Vetoquinol SA, Lure, France) and immediately presented to their
mother. As soon as the umbilical cord had been cut, the ewes
received an iv injection of a nonsteroidal antiinflammatory (flu-
nixine meglumine 1 mg/kg iv; Meflosyl Fort Dodge Santé Ani-
male, Tours, France) and an antibiotic (amoxicillin long action
20mg/kg im; Longamox, Vetoquinol) to prevent pain and septic
complication. Cesarean sectionwas performed to ensure a better
control of the birth process without hormonal treatment and to
allow placenta and cord blood sampling in good conditions.
All animalprocedureswere carriedout inaccordancewith the
accepted standards of humane animal care under the agreement
number 31-242 for animal experimentation from the French
Ministry of Agriculture.
Monitoring BPA exposure and thyroid status
throughout pregnancy
Blood samples were collected twice a week from the begin-
ninguntil the endof treatments, just before anew injection. Serial
blood samples were collected at 0, 2, 4, 6, 8, 20, and 24 h after
the first, 30th, and 58th BPA sc injections to document BPA
pharmacokinetics (PK). The 93rd injection was performed iv,
and serial samples were collected at 0, 2, 4, 8 15, and 30min and
1, 2, 4, 6, 8, 10, and 24 h after the administration to determine
BPA PK parameters and the bioavailability for the sc route.
To avoid any confusion linked to differences in gestational
stages, only the samples collected from the ewes fecundated by
artificial insemination were included in the PK analysis and the
evaluation of the thyroid status during pregnancy. Total and free
T4 and TSH were assayed in one in every four samples collected
twice a week.
BPA exposure of the fetal compartments
During surgery, whenever possible, amniotic fluid, placenta
samples from intercotyledon spaces, mixed cord blood from
both the umbilical vein and artery, and colostrumwere collected
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to assay BPA and BPA-glucuronide (Gluc). The frozen placenta
samples were homogenized in ultrapure water (1 ml water/g tis-
sue) using a tissue homogenizer (Ultra-Turrax T25, IKA
Labortechnik, Staufen, Germany, maximum speed for 1 min in
an ice bath). The total extract was kept in an ice bath and treated
like serum samples. Recovery of the method for both BPA and
BPA-Gluc was evaluated by assaying the molecules in a placenta
from a control vehicle-treated ewe homogenized in water spiked
with either BPA or BPA-Gluc. The BPA concentration in the
extract spiked with BPA at 100 ng/ml was 111 ng/ml, and the
BPA-Gluc concentration in the extract spiked with BPA-Gluc at
1000 ng/ml was 1093 ng/ml.
Thyroid status of ewes and lambs at birth
For the ewes, total T4 and T3 and free T4 were assayed in the
jugular blood collected at the time of cesarean section.
Three samples (1 ml) of the lamb jugular blood were sequen-
tially collected within the first hour of life to monitor the endo-
crine status of the newborn. Free and total T4 and total T3 were
measured in the serum from the cord blood and those three sam-
ples. TSH was assayed in cord blood samples only. At 2 months
of age, blood was collected every 3 h for 12 h to evaluate the
potential recovery of the thyroid function.
BPA and BPA-Gluc assay
BPA was assayed by ultra-performance liquid chromatogra-
phy tandem mass spectrometry as previously described with a
method validated for sheep plasma samples according to U.S.
Food and Drug Administration requirements (19). BPA and
BPA-Gluc were assayed in one of every four samples collected
twice a week in ewes and all the samples collected at birth using
a novel assay method (20). The BPA and BPA-Gluc within- and
between-day coefficients of variation (CV) measured for three
different concentration levels were lower than 13% for both
assay methods. BPA limit of quantification (LOQ) for the first
method was validated in plasma at 1 ng/ml, and the accuracy of
the test ranged from 102–111%. For the second method, the
LOQ were validated at 1 and 20 ng/ml for BPA and BPA-Gluc,
respectively. The method accuracies in serum ranged from 95–
108% and 91–102% for BPA and BPA-Gluc, respectively.
TH and TSH assays
Total and free plasma T4 and total plasma T3 concentrations
were determined using RIA kits (Coat-A-Count kits; Siemens
Healthcare Diagnostics, Los Angeles, CA). The mean intraassay
and interassay CV of three quality control pools were less than
10 and 15% for total T4, respectively, for all assays. The LOQ
for total T4 and T3 assays were validated at 5 and 0.1 ng/ml,
respectively, as the lowest values determined with a CV lower
than 20%. The limit of detection of the free T4 assay was set at
the lowest value of the standard curve, i.e. 1 pg/ml.
TSHwas assayed in 200-l plasma aliquots in duplicate with
a heterologous RIA using a double-antibody separation method
with reagents provided by the National Hormone and Pituitary
Program (Dr. A. Parlow, Harbor UCLA, Torrance, CA) accord-
ing to the National Hormone and Pituitary Program-recom-
mended procedure. Results are expressed in terms of the NI-
DDK-bTSH-1-2 standard. The limit of assay sensitivity was
evaluated at 0.2 ng/ml of the NIDDK-bTSH-1-2 standard. The
mean intra- and interassay CV for three quality control pools
were less than 15%.
PK analyses
The time course of BPA concentrations in samples collected
twice a week and serial samples collected after sc injections were
fitted to a biexponential equation corresponding to a mono-
compartmental model for repeated extravascular administra-
tions with weighting of the data by the inverse square of the
estimated values (1/yˆ2). The estimated parameters were used to
simulate the daily fluctuations of BPA plasma concentrations
throughout the treatment.
The time course of BPA concentrations in serial samples col-
lected for24hafter the iv injectionswere fitted toabiexponential
equation corresponding to a bi-compartmental model with a
1/yˆ2 weighting of the data to determine elimination half-life,
plasma clearance, and distribution volume at steady state.
The 24-h postinjection area under the curve (AUC0–24h) after
the 58th sc administration and the 93rd iv administration was
used to calculate theBPAbioavailability by the sc route. For both
routes, the AUC0–24h estimated by the model were corrected by
the AUC that accounted for the residual concentrations mea-
sured just before the new administration. Subcutaneous bio-
availability was defined as the ratio of the corrected AUC0–24h
for the sc route to the equivalent AUC0–24h for the iv route
expressed as a percentage. The ratio of the AUC0–24h after the
first administration to the one subsequent to the 58th injection
wasusedas an index forBPAaccumulation.All PKanalyseswere
done using WinNonlin version 5.3 software (Pharsight Corp.,
Mountain View, CA).
Statistical analysis
The effect of the treatment on the time course of TH concen-
trations inpregnanteweswasanalyzedbyatwo-wayANOVAwith
treatment and sampling time and their interactions as fixed-effect
factors and animal nested within treatment as a random-effect fac-
tor. The effect of treatment on TH concentrations in samples col-
lected at birth was analyzed using a two-way ANOVA with sex,
treatment, and their interactions as fixed-effect factors. The statis-
tical analysis did not account for twin occurrence. All statistical
analysesweredoneusing general linearmodels onSYSTAT12 soft-
ware (Systat Software Inc., San Jose, CA).
Results
Results are given as mean  SE values.
Maternal exposure to BPA throughout pregnancy
According to themodel predictions, the daily BPA con-
centrations were estimated to fluctuate between a maxi-
mum mean concentration of 240  15 ng/ml and a min-
imumof384ng/ml.Themaximumconcentrationswere
reached on average at 94 6 min after the sc administra-
tion. The ratio of the AUCs0–24h for the 58th sc injection
and the first injection was 0.97, indicating that BPA did
not accumulate in pregnant ewes.
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BPA clearance by iv route was elevated (12.2  1.2
ml/(kg min)], and its terminal half-lifewas short (131.2
10.8 min). The distribution volume at steady state
(917.5  217.0 ml/kg) was higher than the volume of
extracellular fluid. The bioavailability for the sc routewas
evaluated at 35  3%.
Figure 1 shows the time course of BPA and BPA-Gluc
molar serum concentrations assayed in the serial samples
collected after the first and the 58th sc administrations.
The time course of both BPA and BPA-Gluc concentra-
tions was very similar between the two administrations.
Furthermore, the mean ratios of BPA-Gluc to BPA con-
centrations were very similar between the two adminis-
trations (mean ratio 37 and 35 for the first and the 58th
administrations, respectively), indicating that the trans-
formation rate of BPA into BPA-Gluc did not differ be-
tween these two gestational stages.
BPA materno-fetal exposure at birth
One lambshowedaveryhighconcentrationof freeBPA
in amniotic fluid compared with the other animals (lamb
19, 5.4 nmol/ml). A Grubb’s test indicated that this value
was an outlier leading to the exclusion of this animal for
BPA and BPA-Gluc data from amniotic fluid. The con-
centrations in BPA and BPA-Gluc in cord blood and pla-
centa samples from this animal were within the range of
the values observed for all other animals and were thus
kept in the analysis. BPA serum concentrations were very
similar betweenmothers and lambs (Table 1). By contrast,
BPA-Gluc concentrations were about 30- and 50-fold
higher in cord blood and amniotic fluid, respectively, than
in maternal blood at delivery.
Thyroid status of the mother and offspring
Figure 2 shows the time course of total and free T4
serum concentrations in pregnant ewes throughout the
treatment. Therewas a significant interaction between the
time and the treatment on total T4 concentrations with
decreased concentrations in BPA-treated ewes, but there
was no such effect on serum free T4 concentrations.
For all TH and samples assayed at the time of birth,
there was no interaction between the sex and the treat-
ment. Total and free T4 concentrations were higher in the
lamb cord and jugular blood at birth than in the mother’s
blood (Fig. 3). BPA in utero exposure resulted in a signif-
icant decrease in jugular blood concentrations of 29 and
32% for total and free T4, respectively, within the first
hour of life (Fig. 3) and a 33% decrease in total T4 in cord
blood. Total T3 concentration in samples from the first
hour of life showed a trend (P  0.063) toward lower
values in BPA-treated lambs. At 2 months of age, the TH
blood concentrations did not differ between groups (P 
0.05).
TSH concentrations were very rarely above assay sen-
sitivity in both maternal and newborn samples. Too few
values were available to perform analysis. The only indi-
cation fromthis result is thatBPApregnancy exposurewas
not associated with a dramatic increase in TSH secretion,
although we cannot rule out that a moderate nondetect-
able increase might have occurred.
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FIG. 1. Time course of mean ( SE) serum BPA (closed symbols) and
BPA-Gluc (open symbols) concentrations in pregnant ewes (n  6)
treated with daily injections of BPA [5 mg/(kg  d) sc] from GD28 until
the end of pregnancy. BPA and BPA-Gluc were assayed simultaneously
in serial blood samples collected just after the first (solid line) and the
58th (dotted line) administrations.
TABLE 1. BPA and BPA-Gluc concentrations in maternal and fetal samples collected at delivery from ewes treated
with BPA [5 mg/(kg  d) sc from GD28 until the end of gestation]
Maternal blood
(nmol/ml),
n  6
Cord blood
(nmol/ml),
n  11
Amniotic fluid
(nmol/ml),
n  7
Placenta
(nmol/g tissue),
n  10
Colostrum
(nmol/ml),
n  6
BPA 0.18  0.03 0.13  0.02 0.24  0.04 6.54  1.71 0.21  0.03
BPA-Gluc 5.73  1.45 161.72  9.13 312.11  85.86 67.09  10.52 1.69  0.53
BPA-Gluc/BPA 36  12 1380  184 1331  283 18  6 7  2
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Discussion
Experimental data indicate that BPA can cross the placen-
tal barrier (21, 22). Furthermore, in the rat, BPA-Gluc also
appears to cross this barrier in small amounts,whereas the
fetus can exhibit some deconjugation activity toward
BPA-Gluc (23) concomitantly with very low conjugation
activity during early development. Altogether those re-
sults led to the hypothesis that the fetus, more particularly
during the earliest stages of development, could be at risk
for overexposure to bioactive BPA. Our results indicate
that although BPA is transported from the mother to the
fetus through the placenta, the fetus is not overexposed to
unconjugated BPA consequent to the maternal treatment.
This observation is fully consistent with biomonitoring
data obtained inmother/newborn human cohorts indicat-
ing that the newborns exhibit BPA blood concentrations
very similar that of their mothers (24, 25). This rules out
the hypothesis of overexposure of the fetus to unconju-
gated BPA for the late gestation stages but cannot, how-
ever, completely rule out the possibility of fetal overex-
posure for earlier stageswhenhepatic conjugation activity
is still very limited. Neither unconjugated BPA nor BPA-
Gluc accumulates during the course of pregnancy inmoth-
ers. The BPA half-life obtained in our study was very sim-
ilar to the one previously evaluated in prepubertal female
lambs (19). The large volume of distribution of unconju-
gated BPA reported in our study suggests that unconju-
gated BPA iswidely distributedwithin the organism of the
pregnant ewe.
In the present study, unconjugated BPA concentra-
tions were much higher in the placenta than in maternal
blood. In the rat, both the placenta and the fetus express
deconjugation activity (23). Thus, our result could be
explained by the existence of deconjugation activity
within the ewe placenta. If this were to hold true, it
would mean that the placenta itself might be the pri-
mary source of unconjugated BPA for the fetus. In our
study, BPA concentrations in the newborn were within
the same range as those of their mothers (Table 1), sug-
gesting that, at least toward the end of gestation, the
fetus can overcome partially the continuous supply of
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unconjugated BPA by triggering detoxification mecha-
nisms such as phase II metabolism reactions. Such a
mechanism could explain the particularly high levels of
BPA-Gluc measured in all fetal compartments.
In contrast toBPA, thenewbornswere indeedmuchmore
exposed to the glucuronide conjugate than their mothers.
The very high levels of BPA-Gluc encountered in both the
newborn blood and amniotic fluid suggest that BPA-Gluc is
trapped once in the fetal compartment. The source of BPA-
Gluc in the fetus remains to be elucidated. On the one hand,
BPA-Glucmightbefrommaternalorigin.Ontheotherhand,
this BPA-Gluc might be of fetal origin. UDP-glucuronosyl-
transferase activity in the liver starts to develop during fetal
life and continuously increases until birth (26) and so could
have contributed to BPA-Gluc production in the fetal com-
partments in particular toward the end of pregnancy. In ad-
dition, the amniotic fluid might constitute a nonnegligible
source of BPA-Gluc to the fetus after oral ingestion. Indeed,
the fetus is ingesting about 900 ml of amniotic fluid per day
(27), and it can be estimated in our study that this might
provide as much as 100 mg of BPA-Gluc per day at the end
of the treatmentperiod.Given the veryhighaccumulationof
BPA-Gluc in the fetal compartment, the question remains of
the potential deconjugation of BPA-Gluc directly by the tar-
get tissues of the fetus. Suchaprocess could indeed lead to an
in situ reactivation of the conjugate, resulting in an overex-
posure of sensitive target tissues to free bioactive BPA.
Our results showed thatmaternal and fetal exposure to
BPA is associated with disruption of the thyroid function
of both the mothers during pregnancy and the newborns
characterized by a decrease in circulating total and/or free
TH levels. Those results are consistent with epidemiolog-
ical data in humans showing a suggestive inverse relation-
ship between urinary BPA concentrations and total T4 in
adults (7) and one study in rodents showing a transitory
decrease in free T4 concentrations in early postpartum
stages in dams treated with low doses of BPA during preg-
nancy (9). Another in vivo study showed an amplification
of the physiological rise in total T4 occurring around
PND15 in young rats born to and fed by mothers treated
withBPA (8). It is very likely that the apparent discrepancy
between this result and our results in the sheep lies, at least
in part, in interspecies differences in thyroid function on-
togenesis and regulation.
Free T4 concentrations are controlled solely by clear-
ance mechanisms and T4 entrance rate in the blood, i.e.
secretion by the thyroid gland (28), whereas bound and
therefore totalT4 concentrations canalsobemodulatedby
displacement mechanisms from the specific binding pro-
teins, T4-binding globulin and/or transthyretin (29) with-
out modification of free T4 concentrations. In pregnant
ewes, only total T4 concentrations were affected by the
treatment. This effect could be explained by a displace-
ment of T4 from its specific binding proteins. BPA has
almost no binding property toward human TBG and a
very weak one for TTR with very high dissociation con-
stants within the micromolar range and/or very low rela-
tive potencies (30–32).Given the fact that sheepTH-bind-
ing proteins are very similar to human ones, it seems
unlikely that an interaction between BPA andTH-binding
proteins might explain our results.
In vitro studies indicate that BPAmight alter thyroid ho-
meostasis bymodifyingTHsignaling pathways (15, 17, 18).
This antagonistic effect of BPAonTHactionwas confirmed
in vivo in amphibian models in which BPA has consistently
been shown to disrupt thyroid-dependent metamorphosis
(11, 12, 33) and the thyroid-induced expression of fluores-
cent protein in transfected Xenopus tadpoles or zebrafish
larvae (10, 16). It is very difficult to understand how such an
inhibitory effect, very likely to be associated with a certain
degree of resistance to TH, could be associated with a de-
crease in circulating TH. Indeed, it can be assumed that this
resistanceshouldresult inadecrease infeedbackmechanisms
leading to increased TSH and TH secretion. Thus, it seems
unlikely that the decreased TH concentrations in mothers
and newborn lambs after BPA treatment during pregnancy
might result from a direct antagonistic action of BPA onTH
signaling pathways.
A final hypothesis could rely on a possible interaction
betweenBPAand the neuroregulationof thyroid function,
resulting in an inhibition of the TRH/TSH system. Such a
hypothesis would be consistent with our results in lambs.
Indeed, a decreased TSH secretion would lead to a de-
creased synthesis and secretion of TH and more particu-
larly T4, resulting in a decreased entrance rate of T4 in
blood. Such a TSH-dependent suppression of T4 secretion
should result in a simultaneous decrease in total and free
T4 concentrations in blood similar to what was observed
in the newborn lambs. One study on amphibian pituitary
cells indicated that BPA can potentially alter TRH-in-
duced TSH secretion (14). However, this effect was ob-
servedonlywith ahigh concentrationofBPA in the culture
medium (104 M, i.e. 23 g/ml).
Whatever the mechanism of BPA-induced thyroid dis-
ruption is, it can be expected that this modification of the
thyroid homeostasis will be of little consequence to the
mother’s health because the concentration of the free bio-
active form of the hormone is maintained. The situation is
a bit different for the lambs. Indeed, in the newborn, both
total and free concentrations of T4 and, to a lesser extent
total T3, were decreased in BPA-exposed lambs. Given the
critical role of TH in brain development and the exquisite
sensitivity of this organ to TH, it can reasonably be as-
sumed that we are facing a transitory alteration of thyroid
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function thatmight have structural consequences on brain
development. Accordingly, several studies in animalmod-
els report a link between developmental exposure to BPA
and the occurrence of cognitive and/or behavioral altera-
tions and/or an alteration in neural development (34–36).
The critical role of THs andmore particularlymaternal T4
on the development of the central nervous system is one
reason for why our present results should be given full
attention and warrant future studies looking at the effect
BPA on thyroid function.
If we take into account the sc bioavailability, which is
about 30-fold higher than the oral bioavailabilities re-
ported indifferent species (37–40), it canbe estimated that
our dosing regimen was equivalent to an external expo-
sure by oral route about 3000-fold higher than the current
tolerable daily intake [50g/(kg  d) per os], which is itself
about 10-fold higher than the highest estimated human
external exposure [at maximum4.5g/(kg  d) at the 95th
percentile] (41). Although those observations might chal-
lenge the relevance of our results in terms of human ex-
posure, it should be emphasized that the discrepancy be-
tweenour exposure schemeand thehumanexposure is not
that deep if we look directly at the blood concentrations
rather than at the external doses. Indeed, the maximum
concentrations of unconjugated BPA observed in the ewes
was about 15-fold higher than the highest reported blood
concentrations for unconjugated BPA in pregnant women
(42). However, because of the apparent discrepancy be-
tween measured blood concentrations and known PK pa-
rameters for BPA, interpretation of the data from the
standpoint of blood concentrations should be made with
caution.
Independently of all the considerations regarding ex-
posure, our study is the first to show that BPA can alter the
thyroid functionofpregnant animals and their offspring in
a long-gestation species with similar regulation and onto-
genesis of thyroid function as humans. In this context, our
study is proof of concept that BPA, at least for relatively
high concentrations, has a certain potential to disrupt thy-
roid function in fetuses and newborn animals. Even
thoughour study cannot be considered as fully conclusive,
in particular when referring to the exposure scheme that
was used, it lays the foundation warranting further inves-
tigations in terms of mechanism of action of BPA on the
thyroid function, mechanisms and characterization of fe-
tal exposure throughout pregnancy, and possible conse-
quences on central nervous system development. All those
issues are key questions when addressing the potential
health impact of environmental thyroid disruptors. It
seems thus essential to determinewhether this thyroid dis-
ruption might occur for an exposure scheme comparable
to the most likely human exposure.
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